RCT of rapamycin in older adults: study design and rationale, no results reported
This was a randomized controlled trial proposed to test whether rapamycin (sirolimus) could slow aging processes and reduce biomarkers of aging in older adults. The abstract describes the study design, theoretical rationale based on mTOR pathway inhibition, and stated hypothesis that rapamycin may impact aging and chronic disease development. No results, sample size, or effect measures are reported.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 25, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older adults
- Primary outcome
- Reduction in biomarkers of aging processes
- Effect size
- —
- Significance
- Not reported
- Journal
- NOT_REPORTED
- Published
- Jun 25, 2026
Sources
Primary source
- Irina Timofte ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.